Literature DB >> 32399169

Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study.

Natalia Palacios1,2, Éilis J O'Reilly2,3, Michael A Schwarzschild4, Alberto Ascherio2,5.   

Abstract

OBJECTIVE: Antibiotic use is one of the strongest environmental predictors of an altered and less diverse gut microbiome, which has been linked to Parkinson's disease. To our knowledge, no prior study has examined the association between long-term antibiotic use and Parkinson's disease.
DESIGN: We conducted a prospective study of 59,637 women in the Nurses' Health Study who reported total duration of antibiotic use at ages 20-39, 40-59, 60 +, or during the past 4 years. We used Cox Proportional Hazard regression to estimate hazard ratios and 95% confidence intervals for the association between categories of antibiotic use and risk of PD.
RESULTS: One hundred and eighty cases of PD were confirmed during the follow-up. Self-reported antibiotic use at ages 20-39, 40-59, and 60 +, as assessed in 2004, was not significantly associated with PD risk in our cohort. The hazard ratio comparing participants who used antibiotics for 2 or more months vs. 1-14 days at age 20-39 was 0.98 (95% CI: 0.54, 1.78), at age 40-59 was 1.44 (95% CI: 0.88, 2.33), and at age 60 +was 0.88 (95% CI: 0.53, 1.47). Antibiotic use during the past four years, as assessed in 2008, was also not associated with future risk of PD (HR: 1.14, 95% CI: 0.62, 2.10).
CONCLUSION: In this cohort study, we did not observe a significant association between antibiotic use and incidence PD. A major limitation of our study is assessment of exposure, which required many participants to recall their antibiotic use decades in the past. Thus, although the results of this study do not support an effect of antibiotic use on PD risk, larger investigations relying on records of antibiotic prescriptions would provide more definitive evidence.
Copyright © 2020 Natalia Palacios et al.

Entities:  

Year:  2020        PMID: 32399169      PMCID: PMC7201469          DOI: 10.1155/2020/4038375

Source DB:  PubMed          Journal:  Parkinsons Dis        ISSN: 2042-0080


1. Introduction

The involvement of the gastrointestinal system in Parkinson's disease (PD) is increasingly appreciated, and PD is now recognized as a systemic disease. A number of studies have reported alterations in the gut microbiome in PD patients compared with controls. Alterations in specific genera as well as reductions in the overall bacterial diversity of the gut microbiome have been observed in PD [1]. Antibiotic use is associated with rapid changes in taxonomic richness, diversity, and evenness of the gut microbiome [2] and opens up the opportunity of invasion by pathogenic bacteria [3]. Furthermore, antibiotic administration has been shown to alter the metabolism, protein activity, and gene expression of the microbiota [4]. Although, in healthy individuals, the microbiota generally partially recovers after antibiotic treatment has stopped, antibiotic-induced changes can persist for years [2]. The changes in the gut microbiome induced by antibiotic administration have been shown to be similar to those seen in persons with chronic diseases, and gastrointestinal inflammation, which can be induced by antibiotics, has been observed in PD [5]. Long-term use of antibiotics, especially early in life, has been linked with obesity, allergies, and other chronic disorders [6-9]. In the Nurses' Health Study (NHS), self-reported retrospective history of antibiotic use has been linked to increased risk of colorectal adenoma [10]. In this study, we explored among participants in the NHS whether use of antibiotics contribute to predict risk of PD.

2. Methods

2.1. Study Population

The NHS cohort was established in 1976 when 121,700 female-registered nurses enrolled by filling out a mailed health-related baseline questionnaire. Since baseline, NHS participants have completed mailed follow-up questionnaires every two years, reporting their health habits and disease outcomes, including PD. Follow-up rates have averaged over 90% at each follow-up cycle in this cohort. All subjects provided informed consent to participate in the study and the research project was approved by the Institutional Review Board (IRB) at Harvard Medical School.

2.2. Exposure Ascertainment

On the 2004 follow-up questionnaire, NHS participants answered the following question: “for each of the following periods of your life, please add up the total amount of time you used antibiotics (excluding skin creams, mouthwash, and isoniazid)” for time periods between ages 20–39, 40–59, and 60 +. The response categories consisted of “none,” “less than 15 days,” “15 days to 2 months,” “2–4 months,” “4 months–2 years,” “2-3 years,” “3–5 years,” and “5 + years.” The participants also reported the most common reason for the antibiotic use, including respiratory infection, chronic bronchitis, urinary tract infection, dental, acne/rosacea, and other reasons. On the 2008 questionnaire, participants were asked “during the past 4 years, what is the total amount of time you used antibiotics (excluding skin creams, mouthwash or isoniazid)?” They were also asked to report the most common reason for antibiotic use: respiratory infection, chronic bronchitis, UTI, dental, acne/rosacea, and other reasons.

2.3. Ascertainment of PD Cases

PD identification and diagnostic confirmation procedures in the NHS have been described in prior publications [11]. Briefly, we asked NHS participants to self-report incident PD on biennial questionnaires. When a study participant self-reported PD, we sought permission from the study participant to contact their treating neurologist and obtain a medical record. If such permission was granted, we asked the treating physician for confirmation of the diagnosis and a copy of the patient's medical record. A neurologist specialized in movement disorders (M.A.S.) reviewed the medical records and assessed whether a diagnosis of PD was definite, probable, possible, or not indicated. If a medical record could not be obtained, participants were considered to have PD if the treating neurologist or internist indicated that the diagnosis of PD is definite or probable. Only definite or probable cases were included in our analyses.

2.4. Statistical Analysis

In the first set of analyses, we examined, using Cox proportional hazards regression, the association between self-reported antibiotic use at ages 20–39, 40–59, and 60 +, reported in 2004, and risk of incident PD between 2004 and 2012. We calculated the age and multivariate-adjusted hazard ratios (HR) with 95% confidence intervals (95% CI) of PD according to category of antibiotic use with low antibiotic use (1–14 days) as the reference category because this category contained the greatest number of PD cases. Person-time based on age in months was accumulated from baseline (2004) until the date of first PD symptoms, death, last completed questionnaire, or end of follow-up (June 2012), whichever came first. Multivariate analyses were adjusted for age in months, smoking (never or ever), pack-years smoking and postmenopausal hormone (PMH) use (never, past, or current) at baseline in 2004. In subsequent analyses, we examined the association between antibiotic use over the past four years, as reported in 2008 and subsequent risks of incident PD between 2008 and 2012. Due to a limited number of cases in these analyses, we calculated the age and multivariate-adjusted HR of PD comparing participants who reported any antibiotic use to those who reported no antibiotic use during the past four years. Person-time based on age in months was accumulated from baseline (2008) until the date of first PD symptoms, death, last completed questionnaire, or end of follow-up (June 2012), whichever came first. Multivariate analyses were adjusted for age in months, smoking (never or ever) pack-years and postmenopausal hormone (PMH) use (never, past, or current) at baseline.

3. Results

The baseline characteristics of the study participants according to categories of antibiotic use are shown in Table 1. Participants reporting higher use of antibiotics at ages 20–39 and 40–59 were somewhat younger, while the opposite was true for those reported higher use of antibiotic at ages above 60. At all three age ranges surveyed, as well as for past four years of antibiotic use, a higher proportion of participants reporting 2 months or more of antibiotic use were current PMH users and a lower proportion of participants were non- PMH users, compared with those reporting lower levels of antibiotic use.
Table 1

Age-standardized characteristics of the Nurses' Health Study participants at baselinea, b by the extent of antibiotic use.

None1–14 days15 days to 2 monthsMore than 2 monthsMissing
Antibiotic use at age 20–39 a
Number of women7,86129,18010,6834,1777,736
Age, yearsb72.8 ± 6.869.3 ± 6.667.6 ± 6.566.6 ± 6.273.3 ± 6.6
Caffeine, mg/day137.1 ± 125.4139.6 ± 128.8138.9 ± 127.4134.8 ± 128.8131.5 ± 127.0
Alcohol, g/day5.8 ± 10.36.1 ± 10.86.2 ± 10.85.7 ± 10.95.5 ± 10.0
Pack-years smoking11.8 ± 19.113.1 ± 19.912.3 ± 19.012.5 ± 19.413.0 ± 20.2
Nonsmoker, %48.444.344.544.046.0
Past smoker, %44.547.449.450.345.8
Current smoker, %6.98.25.95.58.0
Non-PMH user, %26.421.817.916.321.9
Past PMH user, %52.655.857.856.655.4
Current PMH user, %13.817.320.824.214.9

Antibiotic use at age 40–59 a
Number of women4,21829,74214,3165,4435,918
Age, yearsb71.5 ± 6.969.8 ± 6.868.4 ± 6.867.5 ± 6.774.0 ± 6.2
Caffeine, mg/day144.2 ± 129.4140.5 ± 129.3136.9 ± 125.9129.3 ± 126.2131.6 ± 128.5
Alcohol, g/day6.2 ± 11.06.2 ± 10.95.8 ± 10.35.5 ± 10.35.3 ± 10.2
Pack-years smoking11.8 ± 19.312.8 ± 19.512.7 ± 19.612.8 ± 19.713.0 ± 20.4
Nonsmoker, %49.644.744.643.846.5
Past smoker, %41.847.349.050.544.8
Current smoker, %8.47.86.35.48.4
Non-PMH user, %32.122.417.914.823.1
Past PMH user, %48.355.658.157.753.7
Current PMH user, %11.916.720.123.914.8

Antibiotic use at age 60+a
Number of women9,00125,95312,9005,5686,215
Age, yearsb67.5 ± 6.670.8 ± 6.371.5 ± 6.072.5 ± 6.062.5 ± 6.8
Caffeine, mg/day148.0 ± 133.3140.0 ± 130.1135.9 ± 125.1128.7 ± 126.1132.5 ± 123.8
Alcohol, g/day6.4 ± 11.26.1 ± 10.65.5 ± 10.35.3 ± 9.95.3 ± 10.0
Pack-years smoking12.2 ± 19.312.8 ± 19.513.3 ± 20.613.4 ± 20.311.9 ± 19.5
Nonsmoker, %47.644.643.544.749.0
Past smoker, %43.447.549.349.042.8
Current smoker, %8.97.77.06.17.9
Non-PMH user, %27.121.418.416.622.7
Past PMH user, %52.755.957.656.054.8
Current PMH user, %14.117.019.722.615.8

Antibiotic use during the past four years b
Number of women13,46722,34313,4704,163330
Age, yearsb73.9 ± 6.973.0 ± 6.772.6 ± 6.772.9 ± 6.978.6 ± 6.1
Caffeine, mg/day11.0 ± 18.311.8 ± 18.812.9 ± 19.613.4 ± 20.312.2 ± 18.9
Alcohol, g/day268.5 ± 220.5269.2 ± 221.7265.6 ± 224.7259.3 ± 219.8233.0 ± 209.0
Pack-years smoking5.1 ± 9.24.9 ± 8.94.9 ± 8.84.7 ± 8.74.7 ± 8.7
Nonsmoker, %45.148.151.051.847.4
Past smoker, %6.05.75.24.56.4
Current smoker, %48.746.143.743.546.2
Non-PMH user, %25.620.516.914.621.3
Past PMH user, %58.662.664.664.555.5
Current PMH user, %9.211.614.016.110.2

Values in table are means (SD) or percentages and are standardized to the age distribution of the study population. aBaseline is in 2004 for analyses of self-reported antibiotic use at ages 20–39, 40–59, and 60 + and in 2008 for analyses of past four years of antibiotic use. bValue is not age-adjusted.

Overall, antibiotic use at ages 20–39, 40–59, and 60 + present was not related to risk of incident PD. The HR comparing participants who used antibiotics for 2 months or more with those who used them for only 1–14 days was 0.98 (95% CI: 0.54, 1.78) for the period of 20–39 years, 1.44 (95% CI: 0.88, 2.33) for 40–59 years, and 0.88 (95% CI: 0.53, 1.47) for 65 + years. We also did not observe significant associations between recent 4-year antibiotic use in 2008 and risk of incidence of PD between 2008 and 2012. The HR comparing participants who ever used antibiotics during the past four years, as reported in 2008, compared with participants who never used them was 1.14 (0.62, 2.10). The results of these analyses are presented in Table 2.
Table 2

Antibiotic use by duration of use at ages 20–39, 40–59, and 60 + in 2004 and part four years in 2008 in relation to subsequent PD risk in Nurses' Health Study.

None1–14 days15 days to 2 monthsMore than 2 months p trend

Antibiotic use at age 20–39 a
Number of women7,86129,18010,6834,117
PY57,781219,75781,37931,611
Cases (n = 158)191042312
HRcrudec (95% CI)0.68 (0.42, 1.10)Ref0.68 (0.43, 1.06)1.01 (0.55, 1.83)
HRmultivd (95% CI)0.67 (0.41, 1.09)Ref0.67 (0.43, 1.04)0.98 (0.54, 1.78)0.64
Antibiotic use at age 40–59 a
Number of women4,21829,74214,3165,443
PY31,168223,881108,01340,888
Cases (n = 168)12914528
HRcrudec (95% CI)1.01 (0.55, 1.84)Ref1.16 (0.82, 1.65)1.45 (0.89, 2.35)
HRmultivd (95% CI)1.00 (0.55, 1.83)Ref1.15 (0.81, 1.64)1.44 (0.88, 2.33)0.59
Antibiotic use at age 60 + a
Number of women9,00125,95312,9005,568
PY68,235194,55995,88840,103
Cases (n = 170)19934018
HRcrudec (95% CI)0.70 (0.43, 1.15)Ref0.82 (0.57, 1.18)0.89 (0.53, 1.47)
HRmultivd (95% CI)0.70 (0.42, 1.15)Ref0.81 (0.56, 1.18)0.88 (0.53, 1.47)0.75

Antibiotic use during the past four years (reported in 2008) b
NeverEver p

Number of women13,46839,975
PY49,530146,886
Cases (n = 58)1444
HRcrude (95% CI)dRef1.14 (0.62, 2.09)
HRmultiv (95% CI)bRef1.14 (0.62, 2.10)0.67

aReported in 2004; follow-up: 2004–2012. bReported in 2008; follow-up: 2008–2012. cAdjusted for age as a continuous variable. dAdjusted for age as a continuous variable, pack-years smoking (as a continuous variable), smoking (current, past, or never), and PMH use.

4. Discussion

We did not observe a significant association between retrospective self-reported use of antibiotics at any age between 20 and 60 +, as assessed in 2004, and risk of PD in participants of the Nurses' Health Study. We also did not observe a significant association between recent antibiotic use (during the past four years), as reported in 2008, and risk of PD between 2008 and 2012. An important limitation of our study was assessment of exposure, which required many participants to recall their antibiotic use decades in the past. Further, we have limited information on the type and dose of antibiotics. And, the number of women who reported prolonged use of antibiotics, which is more likely to affect PD risk, was small, as reflected in the wide confidence intervals of our HR estimate. Thus, although the results of this study do not support an effect of antibiotic use on PD risk, larger investigations relying on records of antibiotics prescriptions would provide more definitive evidence.
  11 in total

1.  Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation.

Authors:  Les Dethlefsen; David A Relman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-16       Impact factor: 11.205

2.  Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.

Authors:  Trevor D Lawley; Simon Clare; Alan W Walker; David Goulding; Richard A Stabler; Nicholas Croucher; Piero Mastroeni; Paul Scott; Claire Raisen; Lynda Mottram; Neil F Fairweather; Brendan W Wren; Julian Parkhill; Gordon Dougan
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 3.  Antibiotics in early life: dysbiosis and the damage done.

Authors:  Hadar Neuman; Paul Forsythe; Atara Uzan; Orly Avni; Omry Koren
Journal:  FEMS Microbiol Rev       Date:  2018-07-01       Impact factor: 16.408

4.  Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis.

Authors:  Sara H Rasmussen; Sarita Shrestha; Lise G Bjerregaard; Lars H Ängquist; Jennifer L Baker; Tine Jess; Kristine H Allin
Journal:  Diabetes Obes Metab       Date:  2018-02-25       Impact factor: 6.577

5.  Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.

Authors:  Madelyn C Houser; Jianjun Chang; Stewart A Factor; Eric S Molho; Cyrus P Zabetian; Erin M Hill-Burns; Haydeh Payami; Vicki S Hertzberg; Malú G Tansey
Journal:  Mov Disord       Date:  2018-03-23       Impact factor: 10.338

6.  Long-term use of antibiotics and risk of colorectal adenoma.

Authors:  Yin Cao; Kana Wu; Raaj Mehta; David A Drew; Mingyang Song; Paul Lochhead; Long H Nguyen; Jacques Izard; Charles S Fuchs; Wendy S Garrett; Curtis Huttenhower; Shuji Ogino; Edward L Giovannucci; Andrew T Chan
Journal:  Gut       Date:  2017-04-04       Impact factor: 23.059

7.  The association between antibiotic use in infancy and childhood overweight or obesity: a systematic review and meta-analysis.

Authors:  S A Miller; R K S Wu; M Oremus
Journal:  Obes Rev       Date:  2018-07-23       Impact factor: 9.213

Review 8.  Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle.

Authors:  Filip Scheperjans
Journal:  Curr Opin Neurol       Date:  2016-12       Impact factor: 5.710

9.  Gut microbiota disturbance during antibiotic therapy: a multi-omic approach.

Authors:  Ana Elena Pérez-Cobas; María José Gosalbes; Anette Friedrichs; Henrik Knecht; Alejandro Artacho; Kathleen Eismann; Wolfgang Otto; David Rojo; Rafael Bargiela; Martin von Bergen; Sven C Neulinger; Carolin Däumer; Femke-Anouska Heinsen; Amparo Latorre; Coral Barbas; Jana Seifert; Vitor Martins dos Santos; Stephan J Ott; Manuel Ferrer; Andrés Moya
Journal:  Gut       Date:  2012-12-12       Impact factor: 23.059

Review 10.  The impact of modifiable risk factor reduction on childhood asthma development.

Authors:  Andrew Abreo; Tebeb Gebretsadik; Cosby A Stone; Tina V Hartert
Journal:  Clin Transl Med       Date:  2018-06-11
View more
  3 in total

Review 1.  Parkinson's Disease: A Multisystem Disorder.

Authors:  Helena Nunes Costa; Ana Raquel Esteves; Nuno Empadinhas; Sandra Morais Cardoso
Journal:  Neurosci Bull       Date:  2022-08-22       Impact factor: 5.271

Review 2.  Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond.

Authors:  Ethan G Brown; Samuel M Goldman
Journal:  Neurotherapeutics       Date:  2020-10-09       Impact factor: 6.088

Review 3.  New hope for Parkinson's disease treatment: Targeting gut microbiota.

Authors:  Hong-Xia Fan; Shuo Sheng; Feng Zhang
Journal:  CNS Neurosci Ther       Date:  2022-07-13       Impact factor: 7.035

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.